Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099182 | 0.85 | MGLL (0.49) | RAB9AMGLLTOP2ATOP2BSYK | |
| SCHEMBL2367419 | 0.85 | SLC7A5 (0.50) | SLC7A5NOS3NOS1NOS2LTA4H | |
| SCHEMBL2367046 | 0.84 | KMT2A (0.44) | SLC7A5LTA4HSYK | |
| SCHEMBL2367408 | 0.84 | KMT2A (0.44) | SLC7A5LTA4HSYK | |
| SCHEMBL3050840 | 0.84 | SLC7A5 (0.64) | SLC7A5NOS3NOS1NOS2AURKA | |
| SCHEMBL2367233 | 0.84 | SLC7A5 (0.64) | SLC7A5NOS3NOS1NOS2AURKA | |
| SCHEMBL9175958 | 0.80 | TOP2A (0.46) | RAB9ASLC7A5TOP2ATOP2BNOS3 | |
| SCHEMBL2367757 | 0.79 | SYK (0.60) | LTA4HSYK | |
| SCHEMBL2367199 | 0.79 | ITGB3 (0.60) | MGLLSYKENPP2BACE1 | |
| SCHEMBL2366818 | 0.79 | ITGB3 (0.60) | MGLLSYKENPP2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | RAB9A 2772/4885MGLL 1373/4885SLC7A5 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.